Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of December 2021, with the filing date of December 15, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material change disclosed in this filing is the cessation of securities trading under the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The document does not contain management commentary, financial guidance, or specific risk factors. It serves primarily to notify the SEC of the cessation of securities and incorporates the filing by reference into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the implications of its cessation.
- Confirm the current trading status of Alterity Therapeutics Limited securities on relevant exchanges.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity plans.
- Check for subsequent filings that may provide updated financial data for the development stage enterprise.